Source comparison
Endogenous vs Exogenous: Why Pituitary Preservation Defines the Research Use Case
Synthetic growth hormone (somatropin) works through direct receptor agonism. Injected GH binds to GH receptors in liver, muscle, adipose tissue, and bone, triggering IGF-1 production and downstream metabolic effects. The hypothalamus detects elevated circulati
This comparison does not assign a generated winner or score.
- Synthetic growth hormone (somatropin) works through direct receptor agonism. Injected GH binds to GH receptors in liver, muscle, adipose tissue, and bone, triggering IGF-1 production and downstream metabolic effects. The hypothalamus detects elevated circulating GH and suppresses GHRH secretion; the pituitary detects both elevated GH and reduced GHRH and downregulates somatotroph activity. Within weeks, endogenous GH production drops to near-zero. Stop the injections, and you're left with a suppressed axis that can take months to recover. If it recovers fully at all.
- CJC-1295 for natural GH elevation research avoids this suppression cascade entirely. The peptide doesn't replace GH. It amplifies the GHRH signal that stimulates the pituitary to release GH from its own stores. The hypothalamic-pituitary-somatotroph axis remains active. Negative feedback still occurs, but it modulates amplitude and frequency of pulses rather than shutting the system down. Research groups studying age-related GH decline prioritize this preservation because the goal isn't just transient elevation. It's restoration of youthful pulsatile dynamics without creating long-term dependency.
- A 2009 study in the Journal of Clinical Endocrinology & Metabolism compared CJC-1295 to placebo in healthy adults aged 21–61. After a single 30mcg/kg or 60mcg/kg dose, mean GH levels increased 2- to 10-fold, and IGF-1 levels rose by 1.5- to 3-fold, with effects persisting up to 11 days. Importantly, the pulsatile secretion pattern remained intact. GH surges occurred at physiological intervals rather than as a sustained plateau. This distinction is why regenerative medicine researchers and longevity-focused protocols often select CJC-1295 over synthetic GH when the research question involves chronic use or metabolic optimization rather than acute pharmacological intervention.